Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lurbinectedin

FDA-approved product (powder, intravenous), marketed as Zepzelca.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lurbinectedin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lurbinectedin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lurbinectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

    NCT04894591 · start 2021-06-28

    Registered record
    Registry ID
    NCT04894591
    Conditions
    Extensive-stage Small-cell Lung Cancer
    Interventions
    Zepzelca
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-06-28
    Completion
    2025-06-04
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-stage Small-cell Lung Cancer
    InterventionZepzelca
    PhaseNot recorded
    Registry statusCompleted

  • Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

    NCT04802174 · start 2021-06-01

    Registered record
    Registry ID
    NCT04802174
    Conditions
    SCLC; Small Cell Cancer; Advanced Solid Tumor; High Grade Neuroendocrine Cancers
    Interventions
    Lurbinectedin; Berzosertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-06-01
    Completion
    2027-12-01
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSCLC; Small Cell Cancer; Advanced Solid Tumor; High Grade Neuroendocrine Cancers
    InterventionLurbinectedin; Berzosertib
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

    NCT05101265 · start 2021-03-09

    Registered record
    Registry ID
    NCT05101265
    Conditions
    Advanced Solid Tumor; Hepatic Impairment
    Interventions
    Lurbinectedin; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-03-09
    Completion
    2025-06-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Hepatic Impairment
    InterventionLurbinectedin; Lurbinectedin
    PhasePhase 1
    Registry statusUnknown

  • Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

    NCT05072106 · start 2021-01-14

    Registered record
    Registry ID
    NCT05072106
    Conditions
    Advanced Solid Tumor
    Interventions
    Lurbinectedin; Bosentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-14
    Completion
    2022-01-18
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionLurbinectedin; Bosentan
    PhasePhase 1
    Registry statusCompleted

  • Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

    NCT04607954 · start 2020-12-04

    Registered record
    Registry ID
    NCT04607954
    Conditions
    Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Recurrent Extensive Stage Lung Small Cell Carcinoma; Refractory Extensive Stage Lung Small Cell Carcinoma
    Interventions
    Durvalumab; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-12-04
    Completion
    2031-05-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Recurrent Extensive Stage Lung Small Cell Carcinoma; Refractory Extensive Stage Lung Small Cell Carcinoma
    InterventionDurvalumab; Lurbinectedin
    PhasePhase 2
    Registry statusActive not recruiting

  • Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

    NCT04638491 · start 2020-11-24

    Registered record
    Registry ID
    NCT04638491
    Conditions
    Advanced Solid Tumor
    Interventions
    Lurbinectedin for injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-24
    Completion
    2023-11-04
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionLurbinectedin for injection
    PhasePhase 1
    Registry statusCompleted

  • Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

    NCT04610658 · start 2020-11-23

    Registered record
    Registry ID
    NCT04610658
    Conditions
    Small-cell Lung Cancer; Relapsed Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer
    Interventions
    Nivolumab; Ipilimumab; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-11-23
    Completion
    2023-03-24
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-cell Lung Cancer; Relapsed Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer
    InterventionNivolumab; Ipilimumab; Lurbinectedin
    PhasePhase 1
    Registry statusTerminated

  • Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

    NCT05063318 · start 2020-10-07

    Registered record
    Registry ID
    NCT05063318
    Conditions
    Advanced Solid Tumors
    Interventions
    Lurbinectedin alone; Lurbinectedin+Itraconazole co-administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-10-07
    Completion
    2022-04-21
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionLurbinectedin alone; Lurbinectedin+Itraconazole co-administration
    PhasePhase 1
    Registry statusCompleted

  • Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

    NCT04358237 · start 2020-09-21

    Registered record
    Registry ID
    NCT04358237
    Conditions
    Small Cell Lung Carcinoma
    Interventions
    Lurbinectedin; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2020-09-21
    Completion
    2025-05-20
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Carcinoma
    InterventionLurbinectedin; Pembrolizumab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

    NCT04253145 · start 2019-12-13

    Registered record
    Registry ID
    NCT04253145
    Conditions
    Carcinoma, Small Cell Lung
    Interventions
    PM 01183; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2019-12-13
    Completion
    2025-05
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Small Cell Lung
    InterventionPM 01183; Atezolizumab
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

    NCT02454972 · start 2015-08-25

    Registered record
    Registry ID
    NCT02454972
    Conditions
    Advanced Solid Tumors
    Interventions
    lurbinectedin (PM01183)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-08-25
    Completion
    2020-09-18
    Enrolment
    345

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    Interventionlurbinectedin (PM01183)
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

    NCT02451007 · start 2015-08-12

    Registered record
    Registry ID
    NCT02451007
    Conditions
    Solid Tumors
    Interventions
    lurbinectedin (PM01183)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-08-12
    Completion
    2016-08-19
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    Interventionlurbinectedin (PM01183)
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

    NCT02684318 · start 2015-07

    Registered record
    Registry ID
    NCT02684318
    Conditions
    Advanced Cancer; Ovarian Cancer; Endometrial Cancer; Breast Cancer
    Interventions
    PM01183 + olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2015-07
    Completion
    2019-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Ovarian Cancer; Endometrial Cancer; Breast Cancer
    InterventionPM01183 + olaparib
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

    NCT01831089 · start 2013-09

    Registered record
    Registry ID
    NCT01831089
    Conditions
    Breast Cancer; Ovarian Cancer; Gynecological Cancer; Head and Neck Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Non-squamous Cell Lung Cancer
    Interventions
    PM01183 + paclitaxel +/- bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2016-07
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Ovarian Cancer; Gynecological Cancer; Head and Neck Carcinoma +3 more
    InterventionPM01183 + paclitaxel +/- bevacizumab
    PhasePhase 1
    Registry statusCompleted

  • Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

    NCT02210364 · start 2013-04

    Registered record
    Registry ID
    NCT02210364
    Conditions
    Metastatic Breast Cancer; Pancreatic Cancer; Metastatic Colorectal Cancer
    Interventions
    lurbinectedin (PM01183); capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-04
    Completion
    2016-10
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; Pancreatic Cancer; Metastatic Colorectal Cancer
    Interventionlurbinectedin (PM01183); capecitabine
    PhasePhase 1
    Registry statusCompleted